Novo Nordisk briefly regains the title of Europe's most valuable company

Novo Nordisk, the Danish company behind semaglutide medicines Ozempic, Wegovy, and Rybelsus, reclaimed the title of Europe's most valuable public company on Friday, June 13, 2025, according to Reuters ^[1]. The company's market value reached $367.91 billion, including unlisted shares, based on data from the London Stock Exchange Group ^[1]. That put Novo Nordisk back ahead of German software firm SAP, with Dutch chipmaker ASML in third place ^[1].

The word "regains" in the report signals that Novo Nordisk had lost the top spot before this move, then took it back ^[1]. The source does not explain the specific reasons for the swing, so it is not yet known from this reporting what drove Friday's rise in Novo Nordisk's share price or how long the company held the lead before losing it again, as the headline for this article notes ^[1].

The article does not include details on trading volume, percentage price change, or commentary from company executives or analysts. It also does not compare this market cap figure to Novo Nordisk's value earlier in 2025 or to SAP's own market value on the same day, beyond stating that Novo Nordisk moved above SAP ^[1]. Readers should know that stock market rankings like this can change quickly and do not, by themselves, describe drug availability, pricing, or clinical results.

Why it matters for patients

Stock market value does not directly set the price patients pay for Ozempic, Wegovy, or Rybelsus, and the Reuters report does not draw a line between Novo Nordisk's market capitalization and drug costs or supply ^[1]. Even so, a company's size and investor confidence can shape its ability to fund manufacturing expansion, research on new medicines, and marketing, all of which can affect how widely a drug is available and how it is positioned against competitors in the GLP-1 category ^[1].

Novo Nordisk and rival Eli Lilly, maker of tirzepatide products Mounjaro and Zepbound, have both seen their fortunes tied closely to demand for GLP-1 drugs for diabetes and obesity. This report does not mention Eli Lilly or make any direct comparison between the two companies' market values, so no conclusion about their relative standing can be drawn from this source alone ^[1].

For patients trying to make sense of business headlines about their medications, the key takeaway from this report is narrow: on one specific day, investors judged Novo Nordisk to be worth more than SAP, based on share prices multiplied by shares outstanding, plus unlisted shares ^[1]. That is a snapshot of investor sentiment, not a statement about drug safety, effectiveness, or cost.

What happens next

The Reuters report is dated to a single trading day, June 13, 2025, and does not offer a forward-looking timeline ^[1]. It does not say whether Novo Nordisk kept the top spot in the days or weeks that followed, nor does it mention any scheduled earnings reports, drug approvals, or other events that might move the stock again. Readers looking for the next chapter of this story will need updated reporting beyond what is included here, since this source only captures the market capitalization standings as they stood at that moment ^[1].